HIV treatment relies on antiretroviral medicines that limit the ability of human immunodeficiency virus to replicate. In some situations, changes in the virus can reduce its susceptibility to one or more medicines. HIV drug resistance testing and treatment planning can help healthcare professionals identify these changes and consider them when selecting or adjusting an antiretroviral regimen. Resistance testing is one part of a broader clinical assessment that may also include viral load results, treatment history, medication adherence, previous resistance findings, potential drug interactions, and individual health considerations.
HIV drug resistance testing is used in several clinical situations, including around the time HIV is diagnosed and when treatment is not producing the expected level of viral suppression. Different HIV resistance test methods examine either genetic changes in the virus or its ability to replicate in the presence of specific medicines. The results require clinical interpretation because resistance patterns can be complex, and a test may not identify every previously acquired resistance-associated change. Understanding how testing works provides useful context for HIV treatment planning and long-term clinical monitoring.
HIV reproduces rapidly when it is not adequately controlled by treatment. During replication, genetic changes known as mutations can occur. Some mutations have little effect, while others may alter the virus in ways that reduce its susceptibility to particular antiretroviral medicines. This process is commonly described as HIV antiretroviral resistance.
Resistance can be transmitted when a person acquires an HIV strain that already contains resistance-associated mutations. It can also develop after infection, particularly when viral replication continues while a person is taking an antiretroviral regimen that does not fully suppress the virus. Factors such as inconsistent medication use, drug interactions, absorption problems, or an insufficiently active treatment regimen may contribute to ongoing replication in some circumstances.
HIV medication resistance does not necessarily mean that all antiretroviral medicines will be ineffective. Resistance may affect a single medicine, several medicines within the same drug class, or medicines from different classes. The specific pattern helps clinicians evaluate which treatment components are likely to remain active.
HIV resistance testing methods generally fall into two major categories: genotypic and phenotypic testing. Both approaches provide information about drug resistance, but they examine the virus differently and may be used in different clinical circumstances.
HIV genotype resistance testing examines parts of the viral genetic sequence for mutations associated with resistance to antiretroviral medicines. The detected mutations are compared with established information about how particular genetic changes affect susceptibility to different drugs.
Genotypic testing is commonly used because it can provide clinically relevant information about resistance across several antiretroviral drug classes. The laboratory report may identify individual mutations and provide an interpretation of their likely effect on specific medicines.
Interpretation can become more complex when several mutations are present. Some mutations can interact with others, and the effect of a combination of mutations may differ from the effect of an individual mutation. For this reason, resistance results are generally considered alongside previous test findings and the person's complete antiretroviral treatment history.
Phenotypic testing evaluates how well HIV can replicate in a laboratory when exposed to different concentrations of antiretroviral medicines. Rather than identifying mutations directly, the test measures the virus's susceptibility to particular drugs.
Phenotypic testing may provide additional information when resistance patterns are complex, such as when multiple resistance-associated mutations are present. However, its role depends on the clinical situation, available laboratory resources, and the type of information needed for treatment decisions.
Genotypic and phenotypic HIV resistance test methods are related but not interchangeable. Clinicians may determine which approach is appropriate based on treatment history, viral load, previous resistance results, and the suspected complexity of resistance.
Resistance testing can provide information at different stages of HIV care. Testing around the time of diagnosis can help identify transmitted resistance that existed before antiretroviral treatment began. These findings may influence the selection of an initial treatment regimen.
Testing can also be considered when viral load results indicate that treatment is not maintaining expected viral suppression. In this situation, HIV drug resistance testing may help determine whether resistance-associated mutations have developed and which medicines could have reduced activity.
The timing of testing can affect what is detected. Resistant viral populations may become less prominent after certain medicines are discontinued, while other viral variants become more common. Consequently, a resistance test obtained much later may not reveal every mutation that developed during previous treatment. Historical resistance results can therefore remain relevant to future HIV treatment planning.
Resistance findings are one component of treatment selection rather than a standalone decision-making tool. HIV treatment planning typically considers resistance results together with previous antiretroviral exposure, viral load, CD4 cell count when clinically relevant, medication interactions, tolerability, other health conditions, and the practical ability to follow a treatment schedule.
When resistance is identified, clinicians may evaluate whether individual medicines in the current regimen are expected to remain active. A revised regimen may be considered when existing treatment no longer provides adequate viral suppression. The objective is generally to construct a regimen containing sufficiently active medicines to control viral replication while accounting for the person's broader clinical circumstances.
Treatment decisions may also consider cross-resistance. This occurs when a mutation associated with resistance to one medicine reduces susceptibility to other medicines in the same or a related drug class. Understanding cross-resistance is an important part of interpreting HIV antiretroviral resistance and selecting future treatment options.
No resistance test provides a complete record of every viral variant that has ever been present. Standard tests generally detect viral populations that are present at sufficient levels in the blood sample. Resistant variants present at low levels may not always be identified.
Testing can also be affected by viral load. Some resistance assays require a sufficient amount of circulating virus to generate reliable results. When viral load is very low, standard testing may be technically difficult or unsuccessful. Alternative testing approaches may be considered in selected clinical circumstances, although their interpretation can involve additional limitations.
Another consideration is that laboratory resistance does not fully predict treatment response by itself. Medication adherence, drug concentrations, interactions, treatment history, and other clinical factors can influence whether a regimen achieves and maintains viral suppression.
HIV treatment resistance management involves more than replacing a medicine associated with a resistance mutation. Clinicians typically review the reasons viral replication occurred, because addressing contributing factors can be important for the effectiveness of a revised regimen.
A treatment review may examine medication-taking patterns, dosing schedules, possible interactions with prescription medicines or supplements, previous treatment interruptions, and earlier resistance findings. Historical information is particularly important because a mutation detected years earlier can remain relevant even if it is not identified on a current test.
Ongoing viral load monitoring is also an important part of treatment management. Viral load results help show whether a selected antiretroviral regimen is controlling HIV replication. If viral suppression is not achieved or maintained, additional evaluation can help distinguish resistance from other possible causes.
HIV drug resistance testing and treatment planning therefore function as connected parts of HIV care. Resistance testing provides information about viral susceptibility, while treatment planning integrates those findings with treatment history, laboratory results, medication considerations, and individual clinical circumstances. HIV genotype resistance testing and other HIV resistance testing methods can help characterize HIV medication resistance, but their results require interpretation within the broader treatment record. Continued monitoring and appropriately timed testing can support informed HIV treatment resistance management as antiretroviral therapy is adjusted over time.